Putting the patient first: how pharmacy can get it right
Published: 8 September 2022
This was published when the organisation was the Royal Pharmaceutical Society.
Pharmacy is under significant pressure. Pharmacists across all sectors of the NHS have remained accessible to the public and provided essential services throughout the Covid-19 pandemic. The challenges of the pandemic and its longer-term consequences continue, and these are now being compounded by the escalating cost of living crisis. Many fear what is around the corner, when winter pressures are added to the mix.
With unprecedented levels of burnout among pharmacists, pharmacy closures and the potential for strike action, the Royal College of Pharmacy (RCPharm) calls for three things: professionalism, respect and prioritisation. Specifically:
- We call for pharmacy employers and pharmacy trade unions to come together to a round table meeting to agree principles for a way forward that ensures patients benefit consistently from access to high quality, adequately staffed, safe pharmacy services.
- We call on Governments, NHS organisations and individual pharmacy teams to define clear prioritisation plans, which can be embedded in organisational business continuity plans, that set out the pharmacy services that are essential and must always be provided and which can be de-prioritised at specific levels of pressures.
- We call for zero tolerance of abuse across pharmacy.
Professionalism
Pharmacists are highly trained and regulated health professionals who work right across the NHS: in communities, high streets, general practices and hospitals. The first duty of every health professional is to make the care of patients their first priority. That means pharmacists must do everything they can to maintain pharmacy services for patients, but this must be balanced against ensuring services are safe. Pharmacy services which are closed are unable to help patients at all; but neither are pharmacies with unsafe working conditions.
Therefore, as the professional leadership body for pharmacists, we urge pharmacy employers, trade unions and pharmacists (both employed and self-employed) to work together collaboratively to ensure patients can benefit consistently from access to high quality, adequately staffed, safe pharmacy services.
Respect
Closely linked with professionalism is respect. Pharmacy employers and superintendent pharmacists should respect pharmacists by providing healthy working environments including effective systems, safe staffing, appropriate rest breaks, access to training and development, and a supportive culture. Against a difficult economic backdrop, pay demands and subsequent remuneration needs to be financially sustainable and fair to both pharmacists and pharmacy employers. This includes fair funding from governments for pharmacy services in all sectors. If this mutual respect is missing, it is patients who suffer the most, whether that is through reduced availability of pharmacy services or through safety issues arising from poor working environments and low staff morale.
Crucially, everyone involved in providing pharmacy services must respect patients and, likewise, patients should respect pharmacy teams. The cost of living crisis is putting the vast majority of the population under stress, and this will undoubtedly worsen over the winter. Sometimes these pressures will result in impatience and frayed tempers, but this should never escalate into abusive behaviour. During the pandemic, many pharmacy teams reported an increase in abuse, violence and aggression from some members of the public. De-escalating threatening situations is yet another pressure pharmacy teams face which detracts from delivering patient services. RCPharm has consistently highlighted zero tolerance to abuse and condemns it in the strongest terms.
Prioritisation
One of the causes of impatience among patients is waiting. This brings us to our final point: the need for prioritisation. At a time when pharmacy is already under immense pressure, it is sensible to prioritise the essential services that must be provided if those pressures grow even further. For pharmacy, this will mean temporarily prioritising core pharmacy activities such as the prescribing and supply of medicines along with providing pharmaceutical advice. As winter approaches, clear plans must be developed between NHS organisations and individual pharmacy services which define what must always be provided to ensure safe patient care, and what can be de-prioritised as further pressures hit. Enabling more efficient ways of working, such as allowing community pharmacists to make professional decisions to supply alternative medicines during medicines shortages, and maximising the roles of the whole pharmacy team, is also necessary.
The months ahead will be challenging. However, pharmacists consistently demonstrate great resolve in delivering outstanding patient care. We call on everyone involved with pharmacy services to consider our three points of professionalism, respect and prioritisation, and reflect on how they can realise them in their own practice. Now is not the time for division: only by working together can we develop long-term solutions which benefit all and put patients first.
Download PDF
Download the article in PDF format so that you can access anywhere
Related articles
Pharmacy 2030: a professional vision
Click on the links provided to download a PDF copy of the full vision or the executive summary. Executive summary Introduction The vision: professional roles in pharmacy Achieving the vision: underpinning infrastructure Acknowledgments and strategic links Introduction Every health and care profession, every health service provider and every government has been influenced by the COVID-19 pandemic. It has caused everyone to reflect on whether the strategic directions set five or 10 years ago are still right for a post-pandemic future. Pharmacy is no different: it feels like the right time to set out a new professional vision, building on what has been developed previously to create something that describes the new future. Describing a vision for the future is challenging: some pharmacy teams are already pushing boundaries and delivering care that for others seems a distant dream. What this vision recognises is that everyone is on a journey, and it aims to support all of pharmacy to move forward to a new level of professional practice. It is an evolution from where we are now, not a revolution. The future of pharmacy By 2030, the traditional boundaries between pharmacy sectors will be broken down. Pharmacy teams will work together, both within pharmacy and with the wider multidisciplinary team, to deliver seamless care for patients. Pharmacy teams will take a person-centred approach and care will be provided holistically rather than by clinical condition. They will ensure high quality, safe, effective, cost-effective and sustainable prescribing in all settings. In addition, they will drive high standards of medicines governance, and ensure every aspect of prescribing and dispensing processes are effective and efficient. For pharmacists, this will mean being recognised as medicines experts who take leadership of prescribing in all care settings and who optimise therapeutic outcomes for individual patients. There will be a shift away from checking other professionals’ work towards pharmacists having a clinical, prescribing role to manage the care of individual patients. Pharmacy technicians will lead medicines management processes, both in technical roles focused on the safe and efficient supply of medicines, and in patient-facing roles to support patients’ use of medicines. The breaking down of boundaries between pharmacy sectors will be demonstrated through two key shifts. The first is that seamless patient care will be standard. As a patient moves between care settings, such as at hospital discharge, pharmacy teams will work together to ensure patients’ medicines-related care is supported and to avoid duplication of tasks in the patient’s journey. The second shift is that pharmacy will be more dynamic. Many pharmacy professionals are now actively seeking a portfolio career, working across different sectors. By 2030, a core generalist role for both pharmacists and pharmacy technicians will be developed to enable this flexible portfolio working. This change will be driven by digital and technology developments to enable whole-team working, and clear pathways of professional development which apply to all sectors of pharmacy. “Pharmacy will work together with patients and the multidisciplinary team, using their expertise to make the best use of medicines” The vision: professional roles in pharmacy Being the experts in medicines — "Ensuring the quality and safety of medicines use" The key role of pharmacy professionals, that distinguishes them from other health care professions, is expertise in medicines. This will remain at the centre of pharmacy in 2030, with pharmacy teams ensuring the quality and safety of medicines use through both patient-facing and technical expertise. In 2030, pharmacists will be the clinical lead for safe and effective prescribing within all care settings. Most pharmacists will work in patient-facing roles, consulting with patients: assessing, prescribing, monitoring and reviewing medicines for individual patients. They will be autonomous professionals working within multidisciplinary teams, prescribing in their own right, and managing caseloads of patients who take high risk medicines or who have complex therapeutic needs. These pharmacists will be known as “advanced generalist pharmacists” and will be able to move flexibly between care settings. Some pharmacists will choose to specialise in particular clinical or technical fields, and will become “advanced specialist pharmacists”. Some will develop further into consultant pharmacists who have an influence beyond the individual service to leading whole system improvements. In 2030, pharmacy technicians will lead and be experts in safe and secure purchasing, storage, dispensing and supply of medicines. This will include managing services and providing assurance on safe and effective processes. Pharmacy technicians working in patient-facing advanced level roles will consult with patients, undertake technical aspects of medicines reconciliation and medication review, triage patients, monitor and review blood results, provide patient education, administer medicines (if enabled by legislation/governance arrangements) and liaise with cross sector pharmacy teams. Optimising therapeutic outcomes — Prescribing, monitoring, reviewing, adjusting and stopping medicines n 2030, pharmacy teams will ensure every patient receives high quality prescribing of new medicines and timely, systematic medication reviews. All patients will receive the right care at the right time and the right place. Therapeutic outcomes will be optimised through prescribing, monitoring, reviewing, adjusting and stopping medicines. Pharmacy input will be targeted at: key stages in a patient’s journey such as at transitions between care settings, when patients are acutely unwell, patients who receive high risk medicines and complex therapies, and frail patients. This will improve medicines safety, help manage risk and reduce unnecessary polypharmacy. Optimising outcomes will include delivering greener, more environmentally sustainable services. Pharmacy teams will consider the environmental impact of medicines when prescribing and reviewing medicines, and take action to reduce medicines waste. Providing person-centred holistic care — Empowering patients to make shared decisions about their medicines The core role of pharmacy teams in 2030 will be to provide care for patients holistically, focused on the person rather than their clinical condition or medicines. They will enable person-centred care by having positive conversations with patients and their families/carers, and empowering patients to make shared decisions about their medicines and health. Prescribing decisions will be taken using a Realistic Medicine approach by asking patients “what matters to you”. Pharmacy teams will have regular conversations with patients about medicines. These conversations will be enhanced by pharmacy teams being trained in effective, inclusive communication to address inequalities caused by low health literacy. Pharmacy teams will have essential roles in preventing ill health by taking a holistic approach to care that goes beyond medicines. This will include the provision of health improvement services such as harm minimisation to reduce drug deaths, mental health support, brief interventions to reduce alcohol use, vaccination services and lifestyle advice including using a social/green prescription approach. Improving access to care — Achieving equity of access to pharmacy services Before 2030, all pharmacy teams will proactively offer services in a way that delivers equity of access. They will identify vulnerable patients who need specific support and adapt services for them. A service of particular importance in improving access to care is the NHS Scotland Pharmacy First service: the public’s first port of call for common clinical conditions. By 2030, the vast majority of community pharmacists will be independent prescribers, enabling the Pharmacy First service to be further developed, and it will also be extended into populations who cannot currently access it. By 2030, pharmacy services will be planned alongside wider NHS clinical service provision to ensure equitable access to pharmacy services is achieved across the 7-day period. This does not mean that a full pharmacy service is needed in all settings 24/7 but that patients requiring immediate care, particularly in hospital and out of hours services, are not disadvantaged by the day of the week or time they access services. More generally, access will be improved by enabling services in the way patients want. Pharmacy teams will routinely offer patients a choice of remote consulting, asynchronous consultations and other digital services, as well as in-person care. Similarly, medicines supply will be offered by in-pharmacy collection, delivery services and remote collection, but in all cases, patients will have an opportunity to consult with a member of the pharmacy team, including a pharmacist, every time a medicine is supplied. Leading medicines' governance — Ensuring high-quality prescribing, supply and use of medicines through robust governance Pharmacy teams already play essential roles in medicines governance, focusing on ensuring the safe and effective use of medicines. The crucial difference between the future and today is that in 2030, this will be recognised by others as a leadership role. Currently pharmacy teams both define and implement medicines governance processes: in future, the wider health care team will be involved in implementing the processes. Pharmacy teams will ensure standardised robust work processes, and good governance around the supply of medicines and high-quality evidence-based prescribing. They will consistently implement lean processes to achieve accurate prescribing, dispensing and use of medicines. The supply of medicines will be modernised by 2030. Pharmacy technicians will be the professional leads for the assembly, distribution, and safe and effective supply of medicines. Pharmacists will continue to have an essential role in the medicines supply process through the clinical check. Every prescription for a medicine that is new or has been changed will be clinically checked by a pharmacist, and this will include a conversation with the patient. Accuracy checking will be automated through scanning technology to reduce workload and increase safety. Leading evidence-based practice — Involved in research and strategic leadership to shape service development The creation of a recognised evidence base to underpin the use of medicines and pharmacy practice will continue to be essential in 2030. By then, most pharmacists and pharmacy technicians will have developed research capability and will be involved in research, service development and quality improvement. Pharmacists working in academia and industry will play a leading role both in conducting research and in supporting the development of research skills in others. This evidence will be essential in enabling pharmacists to develop prescribing guidance. By 2030, such guidance will include consideration of the environmental impact of different medicines. Altogether this work will reduce harm, waste and variation. Pharmacists will also have an important role to play in strategic leadership to shape services and models of care in NHS boards and other organisations, wherever medicines are used. Achieving the vision: underpinning infrastructure Using data to deliver high-quality services — Data will underpin personalised care for patients and improved service planning By 2030, data will be used to enhance pharmacy services in a number of ways. Clinical data will be used to target and support decisions. Data will enable provision of personalised care and medicines for patients, including in pharmacogenomics. Decision support software, including artificial intelligence tools, will provide data that will be used to improve the quality and safety of care and prescribing. Data will also be used to make population-based decisions to plan services and prioritise pharmacy resources in response to local needs. In 2030, a national dataset will be available, which will demonstrate the effectiveness and quality of pharmacy services in all settings, enabling the impact of pharmacy services on improving population health to be determined. Clinical outcome measures will be developed, linking patient outcomes with prescribing and administration data. In addition, systems will be developed for obtaining feedback from patients and colleagues about pharmacy teams’ performance to drive continuous service improvement. Harness digital technology and innovation — A single shared electronic patient record will transform health and care services The biggest digital transformation of pharmacy and health care by 2030 will be the introduction of a single shared electronic patient record across all health and care services. This will be a universal patient record into which every professional both reads and writes information, using their existing clinical system as the entry point. Each professional group will have a different view, according to what is appropriate for their role. This record will release clinicians’ capacity, improve safety and enable the provision of better care for patients. Another significant digital development will be full electronic prescribing and transfer of prescriptions across all care settings, removing the need for paper prescriptions. Electronic systems will underpin the recording of administration of medicines in all relevant care settings, including hospitals, care homes, care at home services and prisons. Hospital Electronic Prescribing and Medicines Administration systems (HEPMA) will support triaging of patients to allow clinical pharmacists to target those high-risk patients who need pharmaceutical input as a priority. Technology will also be harnessed to develop patient-facing services including digital consultations and remote monitoring. Developing the workforce — Continual professional development will be embedded across the whole pharmacy workforce By 2030, career development pathways will be in place for all members of the pharmacy team to support professional development, enabling people to flourish and feel fulfilled in their roles. For pharmacists, professional development will be aligned to the RPS curricula for foundation, advanced and consultant practice. Some pharmacists will also choose to complete higher degrees. For pharmacy technicians, professional development will be shaped by a suite of frameworks similar to those for pharmacists. All patient-facing pharmacists will have advanced clinical assessment and consultation skills, and be independent prescribers. Across both pharmacy professions, there will be a cultural shift to a system that is committed to continual professional development. All pharmacy professionals will have a role in supporting the education and development of others. Protected learning time and peer support networks will enable professional development and underpin reflective practice. Leading and participating in research and quality improvement will be a normal professional activity. By 2030, the pharmacy workplace culture will be inclusive, celebrate diversity, create a sense of belonging and be supportive of team members’ wellbeing. Pharmacy professionals will have rest breaks during the working day, flexible working options including portfolio careers, access to wellbeing services and a proper work-life balance. Workforce planning will be carried out across Scotland to ensure that the right skill mix and staffing levels are present in every pharmacy team. This will optimise the roles of pharmacy team members, maximise the time for clinical care, motivate staff and deliver optimal care for patients. Delivering seamless care — All pharmacy professionals will work together across transitions of care By 2030, all pharmacy professionals from all sectors will work together to deliver seamless transitions of care for patients as they move around the health service. Pharmacists will stop being described by their location but by their skills. Care will be planned around patients, for example transforming the supply of medicines on discharge from hospital so they are supplied by the patient’s community pharmacy instead of waiting in hospital. Seamless care extends beyond pharmacy to the wider multidisciplinary health and social care team. Pharmacy will be embedded in multidisciplinary teams and will have well-established referral pathways in and out of pharmacy services. Pharmacy will also play a central role in the new National Care Service to ensure the safe and appropriate use of medicines in care services. Acknowledgments and strategic links Achieving the vision: Key enablers Create a single shared patient record into which every professional both reads and writes information, using their existing clinical system as the entry point Make electronic prescribing, transfer of prescriptions & medicines administration systems available in all settings Improve skill mix within pharmacy teams, combined with effective workforce planning to ensure safe, effective and appropriate pharmacy staffing Support all patient-facing pharmacists to train as independent prescribers NHS Scotland to align the pharmacist post-registration development pathway to the RPS curricula for post-foundation, advanced and consultant practice; and equivalent professional development and credentialing pathways developed for pharmacy technicians Introduce protected learning time for all pharmacy teams to enable professional development and research activities Provide equipment to enable patient-facing digital services and training to maximise its use Establish a national data set to demonstrate the effectiveness and quality of pharmacy services Embed the use of data, such as pharmacogenomics, to help guide treatment decisions and deliver personalised medicine Further embed pharmacy into the wider health and social care multidisciplinary team and develop clear referral pathways in and out of pharmacy services. Acknowledgements We are hugely grateful to all the pharmacists and pharmacy technicians across Scotland who contributed to this vision by participating in focus groups, and sharing their views through surveys, emails, phone calls and meetings. We are also grateful to the pharmacy and non-pharmacy stakeholders who met with us through the consultation period and commented on numerous drafts. This vision was shaped by every single person who was involved: it could not have been created without them, and this final version belongs to them all. Strategic links To make this vision relevant to the strategic direction of travel in Scotland, documents produced by Scottish Government, NHS Scotland and other stakeholders were referenced. The section below highlights some key quotes from some of these documents: Achieving excellence in pharmaceutical care “The evolving focus of pharmacy practice to ensure that people have an understanding of what to expect from their medication requires an acknowledgement that people and their carers rightly wish to be active partners in treatment options." “Pharmacy resource can be targeted through a triage model, focusing on high risk and complex cases.” “Hospital discharge can be a difficult time to support people with adherence to new medication regimens. There is a role for pharmacists and pharmacy technicians in supporting this transition by taking on a greater part in managing care prior to and during discharge.” Scottish Government. 'Achieving excellence in pharmaceutical care: a strategy for Scotland'. August 2017. Scotland’s national clinical strategy “The contribution of pharmacists can be considerably enhanced, with their expertise in ensuring that people with complex medication regimes have their care optimised, and the potential for side effects or harmful interactions reduced." Health care teams should “provide care that is person centred rather than condition focused.” NHS services must “collect and use more information on outcomes, especially those that matter most to patients, rather than clinical data such as biochemical or other surrogate markers”. “While medicines can bring great benefit, they can also cause significant harm. Older people tend to experience worse side effects or consequences of treatment. That is why we should strive to actively manage risk associated with polypharmacy by regularly reviewing and rationalising our patient’s medications.” “Serious harm can result if we don’t listen to the people we care for, and if they are not given the information and support they need to make informed decisions about their care.” “NHS Scotland is a significant contributor to the climate emergency. It emits a large amount of greenhouse gasses, consumes huge amounts of resources and produces copious amounts of waste. We have a moral obligation to help tackle the greatest threat to human health by reducing our impact on the environment. Responsibility rests with us all.” Scottish Government. 'Recover, restore, renew — Chief Medical Officer for Scotland Annual Report 2020-2021'. March 2021 The ALLIANCE’s report on health and wellbeing priorities for the future Care should be “flexible, person-centred which recognises the holistic nature of individuals” and that “being involved in the decision-making process and treated as an expert in their own life circumstances and care” is of the utmost importance to people. “For many people the innovative and accelerated implementation of virtual services improved access, made it quicker and supported more choices for the individual. People have welcomed the use of this technology, and its wider implementation and use should continue.” ALLIANCE. 'Health, wellbeing and the COVID-19 pandemic: Scottish experiences and priorities for the future'. February 2021. The NHS Scotland recovery plan 2021-26 “We will design services so that we minimise unnecessary travel and increase the focus on ‘net-zero’ approaches.” “We will continue to support the move to more health care being provided in the community and closer to home.” We will design a new sustainable system, focused on reducing inequality and improving health and wellbeing outcomes, and sustainable communities." “We will develop and introduce a new pharmacy woman’s health and wellbeing service through our public health services.” “We will also establish a community pharmacy hospital discharge and medicines reconciliation service to help speed up the process for people being discharged from hospital.” “We are investing in developing new digital solutions such as ePrescribing and eDispensing to make the prescribing process paperless.” Scottish Government. 'NHS recovery plan 2021-26'. August 2021 Scottish polypharmacy guidance “With up to 11% of unplanned hospital admissions being attributable to harm from medicines and over 70% of these being due to elderly patients on multiple medicines, there are significant opportunities to reduce this burden by timely and effective interventions.” Scottish Government. 'Polypharmacy guidance — realistic prescribing', Third edition, 2018.
Medicines shortages: solutions for empty shelves — one year on
This was published when the organisation was the Royal Pharmaceutical Society. Introduction Scope of the report Medicines shortages: what happened in 2025? RPS recommendations reviewed by category Ongoing areas for concern Conclusion Acknowledgements 1. Introduction In December 2024, in response to growing concerns about medicines shortages in the UK, the Royal Pharmaceutical Society (RPS) published Medicines Shortages: Solutions for Empty Shelves. The report provides a comprehensive assessment of the causes of medicines shortages, their impact on patients and healthcare professionals, and what more could be done to mitigate and manage them. The report was developed with healthcare professionals, patients and stakeholders across the medicines supply chain. Its recommendations stressed the urgency of work to strengthen the UK’s resilience to medicines shortages, reduce pressure on healthcare teams and ensure patients can access the medicines they need. This ‘one year on’ report provides an overview of progress in line with those recommendations, noting where improvements have occurred, where further work might accelerate progress, and highlighting emerging areas of concern. 2. Scope of the report This report has been informed by a review of policy developments and key stakeholder organisation insights, including through surveying and reconvening the RPS medicines shortages advisory group. This report reflects discussions and feedback from stakeholders. Views of individual advisory group members may vary. This report does not seek to make new recommendations nor present new analysis of medicines shortages. A comprehensive review of how all local systems or individual organisations are implementing recommendations is outside the scope of this work; however, feedback identified through advisory group discussions has been included where relevant for illustration. Discussion is structured around the five categories of recommendations from the original report: UK National Policy (Recommendations 1-6); Predicting Reporting and Responding to Shortages (7-8); Information Flows (9-12); Local Systems (13-17) and; Education, Training and Research (18-20). Finally, the report highlights emerging areas of concern before drawing its conclusions. Recommendations from the original report 3. Medicines shortages: what happened in 2025? Over 2025 and into 2026, there were several national workstreams to improve the management and mitigation of medicines shortages. The medicines shortages report Solutions for Empty Shelves has been referenced throughout, and informed RPS responses to, these workstreams. Whilst some evidence presented to the House of Lords Inquiry into Medicines Security suggests that national shortages may have reduced over 2025, other evidence suggests that the burden of managing medicines shortages for community pharmacies, general practice and hospitals remains unsustainably high. 2026 has already seen some significant medicines shortages. Pharmacy teams have highlighted shortages of several common medicines prescribed in high volumes across the UK (dispersible aspirin, co-codamol and ramipril) that are impacting the workloads of community pharmacy and general practice teams as they find solutions for their patients. This picture is further complicated by reports that the reimbursement system for community pharmacies may, in some cases, impact timely access to medicines. Shortages of epidural infusions have led to a “safety critical and complex” National Patient Safety Alert being issued to facilitate national management of supply. Each organisation using epidural infusions designates an executive lead (or equivalent) to implement national recommendations, supported by clinical leaders in pharmacy, theatres, anaesthesia, maternity care and critical care, a Medicine Safety Officer and Medicine Device Safety Officer. Patients remain at the front line of all these shortages, with one in ten people reporting delays of seven days or longer in obtaining their prescriptions. Delayed access because of a medicine shortage has been cited as a factor in patient deaths. 4. RPS recommendations reviewed by category 4.1 UK national policy Recommendation 1: Publish a UK-wide strategy for shortages In August 2025, a DHSC/NHSE policy paper set out new and ongoing work to improve management and strengthen medicines supply chain resilience. This is to be welcomed and represents some aspects of a national strategy. With the abolition of NHSE and its merger with DHSC, alongside cuts to Integrated Care Boards, this policy direction must now be backed by national leadership and investment. Recommendation 2. Support UK manufacturing infrastructure for medicines The July 2025, Life Sciences Plan recommitted to the Life Sciences Innovation Manufacturing Fund to unlock UK manufacturing infrastructure for medicines (this now includes access for generic manufacturers – several of which have been successful in obtaining funding). In addition, four new NHS aseptic manufacturing sites will begin production in July 2025 – 2027. Recommendation 3: Flexibility in existing medicines regulations to speed up access NHS England, the MHRA and Medicines UK have collaborated in Project Revive. The initiative will encourage manufacturers to relaunch dormant already MHRA-approved licences through a dedicated regulatory pathway and NHS purchasing arrangements. A list of nearly 400 products has been identified by the NHS for the pilot programme, where the NHS considers them a resilience priority, or there is only one or no suppliers MHRA also continues to work, when appropriate and on a case-by-case basis, with manufacturers to expedite applications when shortages are identified to minimise the impact on patients In September 2025, DHSC consulted on proposals to amend the Human Medicines Regulations 2012, to support the ongoing supply and deployment of vaccinations across the UK. This aims to maintain flexibility in the supply of vaccines used during the COVID-19 pandemic. Recommendation 4: Make better use of pharmacists’ skills DHSC consulted in September 2025 on ‘enabling pharmacist flexibilities when dispensing medicines’. Whilst the consultation was welcomed by pharmacy bodies and patient groups, there were concerns that the flexibilities would not go far enough, or would only be available in very limited circumstances. Recommendation 5: Reiterate the legal and ethical responsibilities of the supply chain DHSC are updating their 2013 guidance on Best practice for ensuring the efficient supply and distribution of medicines across the supply chain. The updated version will be published in 2026 to reinforce the behaviours expected in all parts of the supply chain. Recommendation 6: Review the community pharmacy contractual framework Negotiations on the Community Pharmacy Contractual Framework in England are due to start in 2026. Calls for a review of the contractual framework continue, with particular focus on the reimbursement elements of the contract, which anecdotally can contribute to medicines shortages. The NHS’s Independent Economic Evaluation of Pharmacy found that the full economic cost of pharmaceutical services exceeds funding by £2.3 billion . What might accelerate progress (recommendations 1-6) Continued collaborative working across national stakeholders to enable UK responses to medicines shortages The House of Lords Public Service Committee inquiry into medicines security recommends that ‘’The Government should accept that medicine security is, and should be treated as, a national security issue” A swift decision on community pharmacist flexibilities and their implementation, with progress accelerated through early engagement with the digital providers of PMR systems, to enable the changes. Along with communication with GPs, patients and other healthcare colleagues on the parameters of the flexibilities Addressing, in the community pharmacy contract in England, those reimbursement elements that can affect timely access to medicines. 4.2. Predicting, reporting and responding to shortages Recommendation 7: Earlier reporting of shortages by marketing authorisation holders DHSC has worked with representative industry bodies to develop webinars and hold seminars for industry partners on reporting and management of medicines shortages, with future events planned The August 2025 DHSC/NHSE policy paper signalled the intent to consult on options to improve better reporting of supply issues, namely: how to ensure the information provided by suppliers on shortages and discontinuations is sufficient to allow national teams to put timely measures in place to manage supply and mitigate the impact on patients; and the penalties regime used for non-reporting of shortages. Recommendation 8: Enable greater data sharing to support planning and predict demand The August 2025 DHSC/NHSE policy paper highlighted work with suppliers and wholesalers to understand how to improve the efficiency of digital tools to support robust, faster and more targeted responses to issue management. DHSC are trialling the Global Supply Chain Intelligence Programme (GSCIP), which combines several large commercial data sets, to identify shortages before they occur and more rapidly assess the impact of a disruption in one area on others Advisory group members noted reports of effective DHSC and wholesaler data sharing on a case-by-case basis. However, the lack of ‘joined up data’ across the supply chain and data sharing agreements is slowing progress. What might accelerate progress (recommendations 7 and 8) Further discussions on proactive data-sharing between the NHS and manufacturers/suppliers at the national level on issues including digitalisation of the supply chain; better anticipation of demand surges; forecasts of usage from the NHS Continued collaborative work to encourage earlier and better information about supply problems from all manufacturers/suppliers (including parallel importers). 4.3. Information flows Within the scope of this review, it is not possible to evaluate whether local NHS organisations have reviewed how they cascade the information received from national teams about medicines shortages. Neither is it possible to evaluate the extent to which healthcare professionals are proactively accessing information cascades. Recommendation 9: Expand and develop information cascades There has been no review or change of information cascades from national teams. However, nationally, DHSC have engaged with healthcare professionals to understand what information they would find most helpful and how it might be accessed. Work is ongoing, and includes the publication of pharmacist and GP information leaflets and posters. DHSC and NHSE continue to reference the Medicines Supply Tool at events, in publications and communications to support providers of care A Scottish Health Board reported earlier notifications and an improvement in how information is cascaded from DHSC to Health Boards. The independent sector has also worked to improve both information cascades to the sector and use of the Medicines Supply Tool. Recommendation 10: Further involve patient groups to support information sharing Feedback from advisory group members is that the Medicines Shortages Response Group now routinely engages patient groups, particularly for shortages with a high patient impact (Tier 3 and 4) In November 2025, DHSC/NHSE published an information guide for patients developed with patient groups. Subsequent to that work, DHSC is developing a framework to support their patient group engagement. Recommendation 11: Fund, promote and develop the DHSC/NHS Medicines Supply Tool Work continued in 2025 to enable third party software providers to allow access to the Medicines Supply Tool at the point of prescribing via GP prescribing systems. This will increase awareness of the tool and reduce the friction associated with registration and additional logins Feedback suggests that awareness of the Medicines Supply Tool amongst community pharmacists may be increasing. Recommendation 12: Improve systems that provide timely information at the point of dispensing Research for this report found no specific examples of changes to the quality of information wholesaler systems provided to community pharmacists about medicines shortages at the point of dispensing There remains a need for transparency of information from manufacturers and wholesalers so that pharmacy teams have access to up to date and accurate information to support the management of medicines shortages. What might accelerate progress (recommendations 9-12) Investment in the digital infrastructure for information to flow across the supply chain Better system information flows regarding all supply issues from manufacturers to wholesalers to pharmacies. For example, ‘Manufacturer Cannot Supply’ (MCS) coding without an explanation should not be routine Established two-way communication between hospitals and manufacturers/suppliers with clear information to support development of contingency plans to manage medicines shortages Once integrated into GP prescribing systems, the Medicines Supply Tool could be further developed to provide proactive updates, for example, notifications when medicines are no longer in shortage and the development of an app-based format Community pharmacy IT platforms integrating the Medicines Supply Tool at the point of dispensing. 4.4. Local systems Recommendation 13: Develop patient-centred pathways to manage shortages in local systems One Integrated Care Board (ICB) reported greater awareness of shortages and the need to manage them between pharmacies and GPs. In this ICB, community pharmacies reported that they were more confident in using the Medicines Supply Tool, and some had developed electronic pathways to clearly communicate shortages to their practices. Recommendation 14: Invest in the resources needed to manage medicines shortages Some advisory group members were able to point to examples of local investment in teams to support the management of medicines shortages. A large Foundation Trust in London has funded within pharmacy a dedicated staff member with overall oversight of medicines shortage management. An NHS procurement hub in Scotland has invested in staff to review shortages systems and processes across primary and secondary care. Recommendation 15: Develop cross-sector protocols for shortages of life-critical medicines Examples of cross-sector protocols for Pancreatic Enzyme Replacement Therapy (PERT) include the reserve pharmacy model highlighted in Solutions for Empty Shelves, which is still in operation until no longer needed. Advisory group members highlighted a scheme where the NHS Oxford Pharmacy Store holds a buffer stock of unlicensed imports of PERT for community pharmacy within Hampshire and Isle of Wight Integrated Care Board. This enables next day delivery to community pharmacies when supply is needed urgently and cannot be obtained from wholesalers or importers in time. The Regional Specialist Pharmacy Services (SPS) has oversight of the scheme to ensure that stock is used, and a large Foundation Trust within the ICB underwrites the scheme. Recommendation 16: Fund and recruit regional procurement specialists to work across sectors There has been no progress identified in the funding of regional procurement specialists to work across sectors on the management of medicines shortages. However, there are examples of SPS regional procurement leads co-ordinating cross sector activities for high-impact medicines shortages. Recommendation 17: Prioritise supply chain resilience within secondary care contracts In secondary care, a move towards value based-procurement away from price-based procurement has been seen for medicines purchased on NHS frameworks, with supplier accountability increased across a broader base of criteria The need for suppliers to maintain an eight-week buffer stock was reinforced in the August 2025 DHSC/NHSE policy paper. More than eight weeks of UK-held buffer stock is now held for three in every four of all hospital medicines on NHS England frameworks. This links to value-based procurement, with suppliers more likely to be selected for contracts if they operate a well-managed buffer stock programme. What might accelerate progress (recommendations 13-17) A patient representative suggested expanding eligibility for the Healthcare Travel Costs Scheme to enable people facing significant medication shortages to claim back additional travel costs when they cannot access medication locally. 4.5. Education, training and research Recommendation 18: Educate healthcare professionals, patients and the public on shortages Education and awareness-raising activities about medicines shortages for healthcare professionals (including students) and the public included: leaflets, webinars, lectures, and online education programmes. Provision of information for the public in alternative languages would enhance their impact. Recommendation 19: Understand the economic cost of shortages to healthcare organisations and systems There remains limited research into the economic cost of medicines shortages or the effectiveness of interventions to mitigate them. Recommendation 20: Understand the impact of speculation and digital purchasing systems on the supply chain There continues to be reports of shortages where elements of the reimbursement system for community pharmacies may be impacting timely access to medicines. This is adding more weight to calls for a review of community pharmacy reimbursement In February 2026, DHSC launched a consultation on amendments to the information regulations to ‘ensure reimbursement arrangements are more reflective of market conditions and therefore fairer reimbursement for dispensing contractors’. 5. Ongoing areas for concern The RPS medicines advisory group were asked to highlight areas that they felt were of ongoing concern for medicines supply. Ongoing pressure on pharmacy teams. The number of medicines shortages remains high, and their management continues to be complex and time-consuming for all healthcare teams involved. This continues to put significant pressure on pharmacy teams in primary and secondary care. The operational impact of managing medicines shortages may start to impact on patient care as pharmacy resource is pulled away from other activities. In secondary care, system leaders/hospital management at times fail to recognise that the growth in shortages puts an unprecedented burden on procurement and clinical pharmacy teams. NHS reorganisation in England. The loss of staff, with 50% cuts to ICBs and the merger of DHSC and NHS England is creating operational challenges. System-wide reorganisations risk the loss of local links and expertise that support collaborative working to manage shortages. The bandwidth available in teams to support or influence shortage plans may be limited by this disruption. Unintended consequences of actions to secure medicines supply. Many countries are looking at measures to secure their medicines supplies. Initiatives to secure medicines in one country can have unintended consequences for the global supply of medicines. The UK needs to maintain an international view of medicines shortages, and of particular relevance is the EU Critical Medicines Act and Critical Medicines List and their potential impact on supply chains. Northern Ireland EU legislation. EU legislation continues to apply for Category 2 licensed medicines. The EU has provisionally updated their pharmaceutical legislation. Proposals include requirements for industry to have shortage management plans and to report anticipated discontinuations and shortages. This has the potential to require UK suppliers of medicines to Northern Ireland to adopt these measures. Global markets, tariffs and geo-politics continue to affect medicines supply chains. Trade and customs barriers will always have a significant impact on pharmaceutical supply chains globally. The Government, working with international partners such as the United States, the EU and India, may help to strengthen medicine supply chains, including collaborating through the World Trade Organisation. Structural change in the community pharmacy sector. The community pharmacy sector is undergoing significant change. Independent pharmacies now account for two-thirds of the market, with the number of large multiples reducing. Against a backdrop of financial pressures, pharmacy contractors are evaluating their purchasing behaviours to mitigate against potential losses and are increasingly using real-time digital purchasing platforms to ensure that they purchase medicines cost-effectively. The impact of these changes on purchasing patterns across the supply chain needs to be evaluated, including the potential impact on how manufacturers forecast demand. Fragile generics market. Some stakeholders have warned that the ongoing economic fragility of generic medicines supply continues to risk generics market failure. Risk to automation in the medicines supply process. Automation is embedded in medicines supply processes within hospitals, and community pharmacies are increasingly moving towards barcode checking and using robotics space. Removal of barcodes from packs and medicines shortages may begin to risk the efficiency gains made through automation and impact patient safety. Understanding the patient burden of medicines shortages. Impact on the physical and mental health of patients unable to access their medicines needs to be better understood. Including to what extent the patient burden differs, for example, across different socioeconomic groups and/or marginalised communities. 6. Conclusion One year on from the publication of Medicines Shortages: Solutions for Empty Shelves, patients and health professionals continue to feel the impact of medicines shortages. Pharmacy teams remain at the front line of shortages and risk being diverted away from patient focused roles and services as they continue to be drawn into managing fragile medicines supplies. Medicines shortages and the longer-term security of medicines supply chains remain a priority for Governments. Geopolitical influences continue to have a significant impact, as the UK competes in a global commodities market. The report of the Inquiry into Medicines Security highlights the need for the UK to have strong, resilient supply chains. The Inquiry makes recommendations in line with Solutions for Empty Shelves and adds weight to the calls for government leadership on medicines shortages. At a national level, there has been progress across some of the recommendations. Positive collaboration between the national medicines supply teams, the regulator and industry trade bodies has been reported and there is a clear desire to improve the existing systems and minimise the impact of medicines shortages on patients. Much of the progress against the recommendations has been built on the foundations of these well-established systems. To provide a sense of urgency to ongoing and future work to establish more resilient supply chains and reduce the impact of shortages on patients, a national strategy must be supported by senior leaders in Government. This national leadership (and funding) is crucial as other countries develop their own approaches to secure medicines supplies. The Inquiry into Medicines Security recommended the appointment of a Senior Responsible Officer to oversee the resilience of the UK’s medicines supply chain. Whilst there is a clear commitment from DHSC and industry trade bodies to work together to encourage early reporting on medicines shortages and discontinuations, frontline pharmacy teams continue to report instances of medicines going into shortage with little or no advance warning from manufacturers or wholesalers. There is a need for better data collection and insight into patient experience of medicines shortages, learning from high-impact medicines shortages and how patients can be better supported. Structural changes to the community pharmacy sector and developments in electronic purchasing platforms are creating significant shifts in purchasing patterns. The impact on the medicines supply chain of these changes needs to be better understood. Acknowledgements Report authors Catherine Picton, RPS Fellow and Health Policy Consultant Bruce Warner, RPS Fellow and Chair of the RPS Medicines Shortages Advisory Group Advisory group members Charlotte Ansell, Head of Medicines Policy, NHS England Professor Liz Breen, Professor of Health Service Operations, School of Pharmacy & Medical Sciences, University of Bradford Sharon Brennan, Director of Policy and Lived Experience, White Tail Consulting Sean Curley, Principal Pharmaceutical Officer, Department of Health, Northern Ireland James Davies, Director of Research and Insights, Community Pharmacy England Mark Dayan, Brexit and Trade Programme Lead, Nuffield Trust Roger Fernandes, Chief Pharmacist and Clinical Director, King’s College Hospital NHS Foundation Trust Paul Fleming, Technical Director, Medicines UK Anne Hinchliffe, National Contingency Planning Pharmacist, NHS Wales Shared Services Partnership James Kent, Hub Lead for the Procurement Function, Specialist Pharmacy Service Ross MacLagan, Distribution and Supply Chain Policy Manager, Association of British Pharmaceutical Industry Kate Mitchell, Senior Pharmacist, Medicine Supply Team, Medicines Directorate, Department for Health and Social Care Dr Adrian Hayter, Medical Director for Clinical Policy, Royal College of General Practitioners Gayle Robertson, Manager Clinical Technical Services – Pharmacologistic, NHS Greater Glasgow and Clyde Martin Sawer, Executive Director, Healthcare Distribution Association UK Dr Justine Scanlan, Head of the NHS Specialist Pharmacy Service, NHS England and Specialist Pharmacy Service Bernadette Sinclair-Jenkins, Medical Products Supply Lead, HQA, Medicines and Healthcare products Regulatory Agency Sukhy Somal, Head of Community Pharmacy Clinical Services, Black Country ICB Dr Bruce Warner, Chair, Royal Pharmaceutical Society Fellow Additional thanks Alison Ashman Bethan Jones Christopher Pritchard Claymore Richardson Alex Williams Royal Pharmaceutical Society Amandeep Doll Alwyn Fortune John Lunny